Access
To read this story in full you will need to login or make a payment (see right).
Business
Nature 448, 525 (2 August 2007) | doi:10.1038/448525a; Published online 1 August 2007
Open Innovation Challenges
- More Challenges
- Powered by:
nature jobs
Assistant Professor
- University of Texas
- Austin TX United States
International PhD Programme
- MRC Laboratory of Molecular Biology
- Cambridge, UK
Swiss on a roll
Abstract
Smart investors who know the drugs business well are helping to make Zurich's stock market a popular place for biotechnology firms to raise money. Andrea Chipman reports.
At a time when biotechnology companies worldwide are finding it tough to raise money, the Swiss Exchange (SWX) in Zurich is proving to be an alluring financial home."It's an excellent stock market that took the initiative ten years ago to build up a biotech medical segment that makes it attractive," says Ulrich Steiner, an analyst at Swiss bank Clariden Leu in Zurich, adding that smaller biotech companies find it easier to be noticed by investors and raise their profiles in Switzerland.
To read this story in full you will need to login or make a payment (see right).
